Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological...

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• The prognostic significance of programmed death ligand 1 (PD-L1) expression in non-Hodgkin lymphoma (NHL) remains under investigation.
• This study focuses on diffuse large B cell lymphoma (DLBCL), a common subtype of NHL.

Purpose of the Study:

• To evaluate the impact of PD-L1 expression levels on the clinicopathological characteristics of DLBCL.
• To determine the prognostic value of PD-L1 expression in DLBCL patients.

Main Methods:

• A retrospective analysis of 100 de novo DLBCL patients diagnosed between 2013 and 2016.
• PD-L1 expression was assessed using a modified Combined-Positive Score (CPS).
• Clinical, treatment, and outcome data were collected from patient records.

Main Results:

• High PD-L1 expression (≥50%) was observed in 73% of patients and was linked to advanced stage, higher IPI scores, and increased incidence of progressive disease and relapse.
• Five-year disease-free survival (DFS) was significantly lower in patients with high PD-L1 expression (29%) compared to those with low expression (84.8%).
• Low PD-L1 expression (≥5% to <50%) was associated with better outcomes.

Conclusions:

• High PD-L1 expression in DLBCL is associated with aggressive disease features and reduced response to R-CHOP treatment.
• PD-L1 expression level may serve as an independent predictor of DFS in DLBCL.
• Further research is needed to standardize PD-L1 scoring methods and cutoff values.